The neutropenia biologic drug treatment market size has grown strongly in recent years. It will grow from $13.22 billion in 2023 to $14.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.5%. The expansion observed in the historical period can be ascribed to factors such as improved market access and reimbursement, increased patient advocacy and awareness, enhanced physician education and training, advancements in biologic drug development, and the successful outcomes of clinical trials.
The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The expansion anticipated in the forecast period is linked to healthcare cost management, the implementation of patient-centric care models, progress in the development of combination therapies, regulatory changes and approvals, and the adoption of personalized medicine approaches. Key trends projected for the forecast period encompass increased global market accessibility, advancements in manufacturing techniques, streamlining of treatment protocols, the uptake of biosimilars, and the development of long-acting formulations.
The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.
Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.
The neutropenia biologic drug treatment market is expected to face challenges with the introduction of biosimilars following the expiration of patents. Biosimilars are therapeutic agents that closely resemble the original biological products in action but are available at a lower cost. Priced at around 70% of branded drugs, biosimilars have the potential to replace expensive branded alternatives. For example, in May 2022, Biocon Biologics Limited, an Indian biopharmaceutical company, collaborated with Viatris Inc., a US-based healthcare and biopharmaceutical company, to launch Abevmy (bBevacizumab) for the treatment of various cancers, offering a more cost-effective alternative.
Companies in the neutropenia biologic drug treatment market are increasingly investing in the development of innovative drug delivery systems to enhance therapeutic responses and increase efficacy while minimizing side effects. In February 2021, Asalyxa Bio completed its formation and seed funding, advancing ASX-100 into first-in-human trials. ASX-100, a novel spherical particle, releases anti-inflammatory agent salicylic acid directly to over-reactive immune cells, providing a targeted treatment for severe neutrophil-mediated diseases.
Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.
In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.
Major companies operating in the neutropenia biologic drug treatment market report are CVS Health Corporation, Pfizer Inc., Novartis International AG, Sanofi SA, Amgen Inc., Mylan NV, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co. Ltd., Tianjin CanSino Biotechnology Inc., Dr Reddy's Laboratories Ltd., The Unmanned Surface Vehicles Private Limited, Biocon Limited, Dong-A ST Co. Ltd., Akthelia Pharmaceuticals Ltd., Generon (Shanghai) Corporation Ltd., Sandoz International GmbH, Enzychem Lifesciences Corporation, Aprilbio Co. Ltd., Spectrum Pharmaceuticals Inc., S&D Pharma SK sro, Partner Therapeutics Inc., PhytoHealth Corporation, X4 Pharmaceuticals Inc., BeyondSpring Inc., Tanvex BioPharma Inc., Myelo Therapeutics GmbH, Cellerant Therapeutics Inc., Toko Pharmaceutical Industries Co. Ltd., Statera Biopharma Inc. North America was the largest region in the neutropenia biologic drug treatment market in 2023. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.
The neutropenia biologic drug treatment market research report is one of a series of new reports that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
The neutropenia biologic drug treatment market size is expected to see strong growth in the next few years. It will grow to $18.1 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The expansion anticipated in the forecast period is linked to healthcare cost management, the implementation of patient-centric care models, progress in the development of combination therapies, regulatory changes and approvals, and the adoption of personalized medicine approaches. Key trends projected for the forecast period encompass increased global market accessibility, advancements in manufacturing techniques, streamlining of treatment protocols, the uptake of biosimilars, and the development of long-acting formulations.
The increase in global cancer cases is expected to contribute to the expansion of the neutropenia biologic drugs market. The growing incidence of cancer, coupled with a rise in individuals undergoing chemotherapy, has led to an increased prevalence of neutropenia. For example, as of January 2022, the American Cancer Society projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, averaging around 1,670 fatalities per day. Lung, prostate, bowel, and female breast cancer collectively represent 43 percent of all new cancer cases worldwide. Consequently, the surge in global cancer incidence rates is anticipated to drive demand for neutropenia biologic drug treatment in the coming years.
Government initiatives aimed at research and development in healthcare are poised to propel the Neutropenia biologic drug treatment market's growth. These initiatives encompass specific actions, programs, policies, or projects undertaken by government authorities at different levels (local, regional, national, or international) to address specific issues, achieve defined goals, or bring about positive changes in society. Various government bodies are launching healthcare initiatives to support different facets, including neutropenia biologic drug treatment. As an illustration, in 2022, the UK government, through the Department of Health and Social Care, announced a funding commitment of £260 million (US $270.65 million) to boost healthcare research and manufacturing. This allocation by BEIS and DHSC is intended to support NHS-led health research in diagnostics and treatment through new privacy-preserving platforms and clinical research services. Additionally, £60 million (US $63.60 million) was earmarked to facilitate the expansion of life sciences manufacturing in the UK.
The neutropenia biologic drug treatment market is expected to face challenges with the introduction of biosimilars following the expiration of patents. Biosimilars are therapeutic agents that closely resemble the original biological products in action but are available at a lower cost. Priced at around 70% of branded drugs, biosimilars have the potential to replace expensive branded alternatives. For example, in May 2022, Biocon Biologics Limited, an Indian biopharmaceutical company, collaborated with Viatris Inc., a US-based healthcare and biopharmaceutical company, to launch Abevmy (bBevacizumab) for the treatment of various cancers, offering a more cost-effective alternative.
Companies in the neutropenia biologic drug treatment market are increasingly investing in the development of innovative drug delivery systems to enhance therapeutic responses and increase efficacy while minimizing side effects. In February 2021, Asalyxa Bio completed its formation and seed funding, advancing ASX-100 into first-in-human trials. ASX-100, a novel spherical particle, releases anti-inflammatory agent salicylic acid directly to over-reactive immune cells, providing a targeted treatment for severe neutrophil-mediated diseases.
Major players in the neutropenia biologic drug treatment market are focusing on the development of innovative biosimilars, such as pegfilgrastim-pbbk (Fylnetra), to drive market revenues. For instance, in May 2023, Amneal Pharmaceuticals Inc. launched Fylnetra, a biosimilar referencing Neulasta and approved by the Food and Drug Administration (FDA) for the treatment of neutropenia. Fylnetra is available in a convenient pre-filled single-dose syringe.
In November 2022, Biocon Biologics, specializing in the development of biological drugs, acquired Viatris, a US-based company known for developing neutropenia biologic drugs such as pegfilgrastim. This acquisition further strengthens Biocon Biologics' capabilities in research and development, global-scale manufacturing, and commercialization in emerging markets within the biosimilars sector.
Major companies operating in the neutropenia biologic drug treatment market report are CVS Health Corporation, Pfizer Inc., Novartis International AG, Sanofi SA, Amgen Inc., Mylan NV, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co. Ltd., Tianjin CanSino Biotechnology Inc., Dr Reddy's Laboratories Ltd., The Unmanned Surface Vehicles Private Limited, Biocon Limited, Dong-A ST Co. Ltd., Akthelia Pharmaceuticals Ltd., Generon (Shanghai) Corporation Ltd., Sandoz International GmbH, Enzychem Lifesciences Corporation, Aprilbio Co. Ltd., Spectrum Pharmaceuticals Inc., S&D Pharma SK sro, Partner Therapeutics Inc., PhytoHealth Corporation, X4 Pharmaceuticals Inc., BeyondSpring Inc., Tanvex BioPharma Inc., Myelo Therapeutics GmbH, Cellerant Therapeutics Inc., Toko Pharmaceutical Industries Co. Ltd., Statera Biopharma Inc. North America was the largest region in the neutropenia biologic drug treatment market in 2023. The regions covered in the neutropenia biologic drug treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The primary drugs utilized in neutropenia biologic drug treatment include filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, and sargramostim. Filgrastim, a synthetic version of granulocyte colony-stimulating protein, is administered through injections to elevate neutrophil production following chemotherapy. Various types of treatments encompass antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, among others. These medications are accessible through diverse channels, including retail pharmacies, hospital pharmacies, and online pharmacies.
The neutropenia biologic drug treatment market research report is one of a series of new reports that provides neutropenia biologic drug treatment market statistics, including global market size, regional shares, competitors with a neutropenia biologic drug treatment market share, detailed neutropenia biologic drug treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neutropenia biologic drug treatment industry. This neutropenia biologic drug treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The countries covered in the neutropenia biologic drug treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neutropenia biologic drug treatment market consists of sales of cefepime, ceftazidime, piperacillin-tazobactam, and meropenem. Values in this market are 'factory gate values', that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Table of Contents
1. Executive Summary2. Neutropenia Biologic Drug Treatment Market Characteristics3. Neutropenia Biologic Drug Treatment Market Trends and Strategies32. Global Neutropenia Biologic Drug Treatment Market Competitive Benchmarking33. Global Neutropenia Biologic Drug Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Neutropenia Biologic Drug Treatment Market
4. Neutropenia Biologic Drug Treatment Market - Macro Economic Scenario
5. Global Neutropenia Biologic Drug Treatment Market Size and Growth
6. Neutropenia Biologic Drug Treatment Market Segmentation
7. Neutropenia Biologic Drug Treatment Market Regional and Country Analysis
8. Asia-Pacific Neutropenia Biologic Drug Treatment Market
9. China Neutropenia Biologic Drug Treatment Market
10. India Neutropenia Biologic Drug Treatment Market
11. Japan Neutropenia Biologic Drug Treatment Market
12. Australia Neutropenia Biologic Drug Treatment Market
13. Indonesia Neutropenia Biologic Drug Treatment Market
14. South Korea Neutropenia Biologic Drug Treatment Market
15. Western Europe Neutropenia Biologic Drug Treatment Market
16. UK Neutropenia Biologic Drug Treatment Market
17. Germany Neutropenia Biologic Drug Treatment Market
18. France Neutropenia Biologic Drug Treatment Market
19. Italy Neutropenia Biologic Drug Treatment Market
20. Spain Neutropenia Biologic Drug Treatment Market
21. Eastern Europe Neutropenia Biologic Drug Treatment Market
22. Russia Neutropenia Biologic Drug Treatment Market
23. North America Neutropenia Biologic Drug Treatment Market
24. USA Neutropenia Biologic Drug Treatment Market
25. Canada Neutropenia Biologic Drug Treatment Market
26. South America Neutropenia Biologic Drug Treatment Market
27. Brazil Neutropenia Biologic Drug Treatment Market
28. Middle East Neutropenia Biologic Drug Treatment Market
29. Africa Neutropenia Biologic Drug Treatment Market
30. Neutropenia Biologic Drug Treatment Market Competitive Landscape and Company Profiles
31. Neutropenia Biologic Drug Treatment Market Other Major and Innovative Companies
35. Neutropenia Biologic Drug Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Neutropenia Biologic Drug Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on neutropenia biologic drug treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neutropenia biologic drug treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Drug Type: Filgrastim; Pegfilgrastim; Lenograstim; Lipegfilgrastim; Sargramostim
2) By Treatment Type: Antibiotic Drugs; Granulocyte-Colony-Stimulating Factor (G-CSF); Antifungal Drugs; Other Treatment Types
3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Pharmacies
Key Companies Mentioned: CVS Health Corporation; Pfizer Inc.; Novartis International AG; Sanofi SA; Amgen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- CVS Health Corporation
- Pfizer Inc.
- Novartis International AG
- Sanofi SA
- Amgen Inc.
- Mylan NV
- Baxter International Inc.
- Teva Pharmaceutical Industries Ltd.
- Kyowa Kirin Co. Ltd.
- Tianjin CanSino Biotechnology Inc.
- Dr Reddy's Laboratories Ltd.
- The Unmanned Surface Vehicles Private Limited
- Biocon Limited
- Dong-A ST Co. Ltd.
- Akthelia Pharmaceuticals Ltd.
- Generon (Shanghai) Corporation Ltd.
- Sandoz International GmbH
- Enzychem Lifesciences Corporation
- Aprilbio Co. Ltd.
- Spectrum Pharmaceuticals Inc.
- S&D Pharma SK sro
- Partner Therapeutics Inc.
- PhytoHealth Corporation
- X4 Pharmaceuticals Inc.
- BeyondSpring Inc.
- Tanvex BioPharma Inc.
- Myelo Therapeutics GmbH
- Cellerant Therapeutics Inc.
- Toko Pharmaceutical Industries Co. Ltd.
- Statera Biopharma Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 14.08 Billion |
| Forecasted Market Value ( USD | $ 18.1 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | Global |
